This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Syneron Announces Resignation Of Chief Financial Officer

YOKNEAM, Israel, Aug. 23, 2012 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, announced today that Asaf Alperovitz has resigned from the position of Chief Financial Officer to pursue a new career opportunity. Syneron's Board of Directors has appointed David Schlachet as interim Chief Financial Officer, effective as of August 24, 2012, and has initiated an executive search process to find a permanent replacement.

(Logo: )

Mr. Schlachet is a current member of Syneron's Board of Directors and previously served as Syneron's Chief Financial Officer from 2004 to 2005 and as the Company's Chief Executive Officer from 2005 to 2007. He retired from the position of Chief Executive Officer in 2007 and concurrently joined the Company's Board of Directors. During his tenure as interim Chief Financial Officer, Mr. Schlachet will suspend his membership in Syneron's audit committee.

Louis P. Scafuri, Chief Executive Officer of Syneron, said, "Given his prior executive leadership positions and current Board position with Syneron, David is well prepared to manage the day-to-day activities of the finance team as we conduct the recruitment search for a new CFO. We have a strong finance team in place and I am confident that they will continue to perform under David's leadership."

Mr. Scafuri added, "We recently reported our second quarter results, which demonstrated our ability to drive revenue growth and an improving profitability profile. We remain on track to meet our key milestones for the remainder of the year, including the current North American launch of the elos Plus next generation multi-platform system, the expected launch of exciting new body contouring products, and additional regulatory approvals in key Asian countries for the elure Advanced Skin Brightening system."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.70 -0.60%
FB $101.91 0.90%
GOOG $683.11 -0.15%
TSLA $150.47 4.73%
YHOO $26.76 -1.25%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs